Search

Community Bulletin: SRP-9001 Clinical Trial Updates
Sarepta Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Corporate Developments on August 7, 2019
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Statement on ICER Draft Evidence Report for Treatments for Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments
Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy
Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019
A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)